Background and Aims: Treatment of anastomotic biliary strictures (ABSs) after orthotopic liver transplantation by endoscopic insertion of multiple plastic stents (MPSs) is well established. The use of covered self-expandable metal stents (cSEMSs) for this indication is less investigated.
INTRODUCTION
Anastomotic biliary stricture (ABS) is a major cause of morbidity after orthotopic liver transplantation (OLT) with a reported incidence of 8% to 20%. [1] [2] [3] Nonsurgical management of ABS has become the first-line treatment strategy. 4 This therapy consists of endoscopic or percutaneous stent placement, hydrostatic balloon dilation, or a combination of both techniques, which can be applied via endoscopic retrograde cholangiography (ERC) or percutaneous transhepatic cholangiography technique. 5 Primary success rates of up to 90% are reported but strictures recur in approximately 20% of patients. 6 Even after ABS recurrence, endoscopic retreatment is feasible with 90% to 100% resolution rates. 3, 7, 8 In most centers, placement of multiple plastic stents (MPSs) with an increasing number of stents at each stent exchange is used. Patients with ABSs typically need 4 to 5 interventions by ERCP until the stricture is dilated sufficiently. [9] [10] [11] [12] However, from the patients' perspective, repetitive ERCP sessions for plastic stent exchange have a negative effect on compliance and acceptance of this treatment approach. With covered self-expandable metal stents (cSEMSs), this limitation can be challenged: Efficacy of cSEMSs in the treatment of benign strictures has been shown to be noninferior to MPSs. 12 Furthermore, implantation of a single cSEMS has a diameter equivalent to several 10F plastic stents but offers longer patency 13 ; therefore, stent exchanges are required less frequently as the stent indwelling time of cSEMSs is usually much longer than for plastic stents. Only a very limited number of randomized trials comparing the efficiency of MPSs versus cSEMSs for the treatment of ABSs are available. [15] [16] [17] We conducted an open-label, multicenter, randomized trial to compare MPSs and cSEMSs with regard to the number of endoscopic sessions, adverse events, and success rates in the treatment of ABSs.
PATIENTS AND METHODS

Patient selection
The study was conducted as a prospective, open-label, multicenter trial (clinical trials registration number: NCT01393067) in 4 European liver transplantation centers after approval of their local ethics committees (Frankfurt University Hospital, Germany; Essen University Hospital, Germany; Department of Gastroenterology, IRCCS Cà Grande, Ospedale Policlinico, Milan, Italy; Department of Gastrointestinal and General Surgery, Helsinki University Central Hospital, Helsinki, Finland). All patients who, between 2012 and 2015, underwent deceased donor OLT for end-stage liver disease or acute liver failure were eligible for this study if ABS was suspected or confirmed by ERC. All patients included in this study did not participate in other studies. Patients with nonanastomotic strictures, including ischemic-type biliary lesions or biliodigestive anastomosis, were excluded. ABS was clinically suspected if signs of cholangitis, pruritus, or progressive jaundice were observed by clinical examination and/or abdominal ultrasonography revealed cholestasis. After obtaining informed consent and confirmation of ABS via ERC, patients were randomized 1:1 to receive either MPS or cSEMSs. ABS was defined as a stricture occurring at or directly adjacent to the choledocho-choledochal anastomosis. Patients were not included in the study if either MPSs or cSEMSs were judged technically not feasible or reasonable by the investigator.
Endoscopic treatment
For ERCP therapeutic duodenoscopes (eg, TJF160 VR or TJF Q180 VR; Olympus Corporation, Tokyo, Japan) were used by endoscopists with experience of >1000 ERCs.
The stricture grade was determined by a modification of a former published grading system, which was assessed by fluoroscopic imaging (stricture grade A, 99%-100% of luminal diameter; B, 90%-99%; C, 50%-90%; D, <50%; E, 0%). 3 After confirmation and grading of ABSs, endoscopic sphincterotomy was performed in all patients. Whether to perform hydrostatic balloon dilatation before stent placement (eg, 6 or 8 mm MaxForce balloon catheter; Boston Scientific, Ratingen, Germany) was at the discretion of the investigator. Participants were treatment naive with regard to ABSs, except for previous emergency treatment with single plastic stents in cases of acute cholangitis.
In the MPS group, the investigator inserted as many plastic endoprostheses as possible choosing the optimal diameter at his discretion (eg, 7F, 10F, 11.5F). Every 6 to 12 weeks, stent exchange ERC sessions were scheduled, and the number and diameter of the MPSs were increased as considered appropriate by the investigators. Within this trial, 4 different plastic stent types were used: straight plastic stents with 2 flaps, plastic stents with a duodenal bend and 2 flaps, plastic stents with a central bend and 2 flaps, or double pigtail stents.
Patients randomized to the cSEMS group received a fully covered stent with a diameter of 10 mm. Three different cSEMSs were used within this trial; all were fully covered and without antimigration flaps. For retrieval, 2 stent types had a small retrieval flap and 1 cSEMS had a big lasso. Two cSEMS were placed across the papilla and 1 cSEMS type was placed completely inside the common bile duct (CBD). After 4 to 6 months, an ERC session was scheduled for cSEMS removal. In both groups, treatment was defined to be successful if no relevant ABS was left at the stent removal/exchange session. Patients regularly visited the hospitals' outpatient clinic, and clinical examinations including blood sampling and sonography were performed. Endoscopic therapy was determined successful in cases of radiomorphologic resolution of the stricture with persisting narrowing of the anastomosis of less than 30% of the diameter of the CBD.
Investigators were allowed to perform ERCP earlier than per protocol if there was clinical suspicion of stent occlusion or migration. In cases of any adverse events, eg, stent migration, stent dysfunction, or hemobilia, a crossover to the other treatment arm was advised. During a follow-up period of 1 year, patients presented routinely every 2 to 3 months in our interdisciplinary transplantation clinic where abdominal ultrasound and liver function tests were performed to evaluate whether a relevant ABS recurrence occurred.
The primary endpoint was the number of ERC sessions until resolution of ABS. Secondary endpoints were frequency of adverse events, treatment success rates of the respective stent regimens, time to treatment success, and recurrence of ABS during follow-up.
Statistical analysis
Fax randomization was provided by the Institute of Biostatistics and Mathematical Modeling, Goethe University, Frankfurt, Germany. Center-stratified block randomization was conducted using the R package "blockrand" (R Development Core Team [2010] [R Foundation for Statistical Computing, Vienna, Austria]). Patient-related data were pseudonymized in case record forms and collected at the study center in Frankfurt for analysis in perprotocol and intention-to-treat fashion. The primary endpoint of this study was the number of ERC sessions. We assumed that the number of interventions was described by random variables that follow a Poisson distribution with parameters l1 und l2. The mean number of interventions was thereby compared using a Poisson test. The test was 2-sided with a level of significance of a Z 5%. Data from the literature were used to determine l1 and l2. The estimated number of investigations for MPS treatment was 5, and the estimated number of investigations for cSEMS was 2 (implantation and explantation). 18 With 25 patients in each therapy group, a 2-sided Poisson test can detect a difference between the 2 study groups with a level of significance of a Z 5% and a power of 1 À b of at least 80%.
Data analysis
Continuous variables are shown as the median and range, and categorical variables are reported as frequencies and percentages. Differences among different patient cohorts were determined using the 
RESULTS
Fifty-eight patients were enrolled between July 2012 and April 2015; 48 patients completed follow-up (MPS group, n Z 24; cSEMS group, n Z 24) (Fig. 1) . Of 58 eligible patients, 6 had no relevant stenosis verified by fluoroscopy within ERC. One patient was excluded from the study because of a technical failure at randomization and 1 patient withdrew consent after enrollment. Two patients died during follow-up from non-study-related morbidity. One patient (cSEMS group) died after multiorgan failure caused by urosepsis. The other patient (MPS group) died at home supposedly from cardiac arrest.
The median age of the patients treated with MPS was 58.5 years (range, 32-72 years) compared with 57 years (range, 32-69 years) in the cSEMS treatment group (P Z .718). Gender distribution was similar in both groups; 6 females were treated with MPS and 10 females received cSEMS treatment (P Z .359). The most frequent indication for OLT was liver cirrhosis caused by viral hepatitis (MPS group, n Z 10, 41.7%; cSEMS group, n Z 8, 33.3%) followed by hepatocellular carcinoma in cirrhotic patients (MPS, n Z 5, 20.8%; cSEMS, n Z 4, 16.7%) ( Table 1) . Time between OLT and endoscopic treatment was a median of 222 days (range, 8-3189 days) in patients treated with MPS and 163 days (range, 8-7779 days) in the cSEMS group (P Z .861). ABSs were filiform (A) in 8 (16.7%), high-grade (B) in 29 (60.4%), moderate (C) (n Z 10, 20.8%), or low-grade (D) (n Z 1, 2.1%) before endoscopic treatment. ABS grade did not significantly differ between both treatment arms (P Z .053). Balloon dilatation of ABS was performed in 14 (58.3%) and 10 (41.6%) patients before the first stent placement in the MPS versus cSEMS treatment arm (P Z .387).
In the cSEMS group, we observed hepatofugal stent migration in 8 patients (33.33%). In 4 (50%) of these cases, ABS was already resolved and no further endoscopic treatment was necessary at the time of follow-up. One patient (12.5%), however, later developed recurrent symptomatic ABS and had to undergo repeat treatment. In the remaining 4 (50%) patients, ABS was still detectable at follow-up ERC and crossover to treatment by MPS insertion was initiated. In 5 of the 8 patients (62.5%) with spontaneous cSEMS migration, the cSEMS was excreted via naturalis on the day of ERC; in 3 cases (37.5%), the dislocations were not observed by the patient or the investigator.
In 1 patient in the MPS group (4.1%), severe hemobilia was observed during stent exchange, and therefore a cSEMS was inserted to stop bleeding. In 1 patient (4.1%) who was initially treated with MPS, treatment was discontinued because of spontaneous development of a bilioduodenal fistula no longer requiring biliary drainage. In 3 patients (12.5%), MPS treatment was switched to cSEMS treatment, 1 because of severe bleeding, 1 insisted on receiving a cSEMS because of a very long driving distance to the hospital, and 1 patient for unknown reasons.
Intention-to-treat analysis
Patients treated with MPS underwent a median of 4 (range, 3-12) ERCs, whereas patients in the cSEMS group underwent a median of 2 (range, 2-12) sessions until ABS resolution when including the crossover treatments (P < .001) (Fig. 2, Table 2 ). The number of implanted stents per patient until end of treatment was 8 (range, 2-32) in the MPS group and 1 (range, 1-24) in the cSEMS group (P < .0001), including patients who were converted from cSEMS to MPS treatment and vice versa. Investigators used a median of 2.5 (range, 1-5) stents for upsizing at every programmed stent exchange in the MPS group compared with only 1 stent (range, 1-4) in the cSEMS group (P < .0001). Median time until the end of treatment was 229.5 days (range, 59-490 days) in the MPS group and 178.5 days (range, 65-551 days) in the cSEMS group (P Z .458). Both treatment arms achieved high initial treatment success rates of 95.8% (n Z 23) for patients treated with MPS and 100% (n Z 24) for those treated with cSEMSs (P Z 1). There was no difference found in the incidence of ABS recurrence between the 2 different treatment groups with 5 relapses (20.8%) (P Z 1) in each group after a median follow-up of 500 days (range, 48-1317 days) after endoscopic treatment.
Per-protocol analysis
Twenty of 24 patients (83.3%) who were initially allocated to treatment with MPS ( Fig. 3) and 18 of 24 patients (75%) who were treated with cSEMS completed endoscopic treatment of ABS (P Z 1) ( Table 3) . ABS grade before treatment did not differ between the groups. Gender distribution did not significantly differ with 5 females in the MPS group and 7 females in the cSEMS group (P Z .569). The median age of patients receiving MPSs was 58.5 years (range, 32-72 years) compared with 58.5 years (range, 37-69 years) for patients treated with cSEMS (P Z .675). A median of 239.5 (range, 59-490) and 177.5 (range, 65-249) treatment days was required for ABS resolution for patients in the MPS versus cSEMS groups, respectively (P Z .015). In the MPS group, a median of 4 (range, 3-12) versus 2 (range, 2-2) endoscopic interventions in the cSEMS arm were performed (P < .0001) and a total of 9 (range, 2-32) versus 1 stents were inserted (P < .0001). ABS recurrence was observed in 20% versus 22.2% of patients in the MPS versus cSEMS groups, respectively (P Z 1). During a median follow-up of 508 days (range, 65-1183 days) (P Z .093) for patients treated with MPS and 399.5 days (range, 189-1048 days) for those treated with cSEMSs (Fig. 4) , the recurrence rate was not significantly different at 20% (n Z 4) versus 22.2% (n Z 4) (P Z 1).
DISCUSSION
Endoscopic therapy is the standard treatment modality for ABS after OLT, and insertion of multiple plastic stents is widely practiced. We previously published that this approach is highly effective with a success rate of about 90%, and that ABS recurrence after initial stricture resolution can again be successfully treated endoscopically. 3 However, as several ERC sessions for stent exchange are required until stricture resolution, a more efficient and, for the patient, more comfortable alternative may increase acceptance of this therapy. Recently, several investigators reported cSEMSs to be safe and efficient for treatment of benign as well as malignant CBD strictures, ie, tumor obstruction, non-neoplastic strictures, and particularly ABSs. 13, 19, 20 In this prospective randomized study, we observed that cSEMS treatment of ABSs offers a reduction in treatment time and number of interventions compared with the current treatment standard, ie, MPS insertion. Both the intention-to-treat as well as the per-protocol analyses demonstrated fewer interventions and stents per patient for cSEMSs. For MPSs, a median of 4 ERC examinations was needed compared with 2 sessions until ABS resolution in the cSEMS group (P < .001) in the intention-to-treat analysis. A median of 8 stents was used until the end of treatment in the MPS group and 1 in the cSEMS group. This is in line with a recently published trial where the . Recurrence-free survival. A, Kaplan-Meier curve of ABS recurrence (log-rank test, P Z .9). Not achieved in 50%; therefore, no median survival rates could be calculated. B, Percentage ABS recurrence (median þ interquartile range, P > .2). cSEMS, Covered self-expandable metal stent; MPSs, multiple plastic stents.
mean number of ERCPs to achieve stricture resolution was lower for cSEMSs (2.14) versus plastic stents (3.24) (mean difference, 1.10; 95% confidence interval, 0.74 to 1.46; P < .001) in this randomized trial. 14, 15 ABS recurrence rates were equal in both treatment groups after 1 year of follow-up. This may indicate that MPSs and cSEMSs provide similar radial expansion force, and clinical results may be equal for similar treatment duration. However, long-time ABS recurrence of about 20% after initial endoscopic treatment success indicates that treatment duration should be long enough irrespective of the stent type, MPS or cSEMS. 3 Comparative trials have not yet addressed the most appropriate treatment duration, however, expert opinion advises treatment at at least 4 to 6 months. 13 In this study, 8 of 24 (33%) cSEMSs spontaneously migrated. Four of these patients did not need any further treatment because there was no stricture remaining. The other 4 patients continued treatment with MPSs. We used 3 different types of cSEMSs within this trial. Some were placed across the papilla, and 1 cSEMS type was placed completely inside the CBD. We could see a tendency toward less migration for cSEMSs when placed completely within the CBD but because of low patient numbers, no statistically valid calculations or statements can be made. Considering the tendency toward less stent migration with cSEMSs that are placed completely within the bile duct, our findings are in agreement with the results of Kaffes et al. 15 Therefore, new antimigration measures for cSEMSs are needed as well as randomized trials comparing different types of cSEMSs. An ideal cSEMS would have a high radial expansion force without spontaneously migrating after or even before stricture resolution. Only 1 patient with a cSEMS migration developed recurrent ABS. 4, 13 Some limitations have to be taken into account. The study is quite small by number; however, it is multicenter and prospective, thereby reflecting daily practice.
Although cSEMSs seem to have advantages over MPSs, cSEMSs are still quite expensive, and a thorough cost analysis was not carried out. However, the reduced number of treatments should at least counterbalance the increased costs of the stent. Furthermore, there are several different kind of stents available, and we did not limit use to one single kind of stent. Therefore, it is possible that some cSEMSs are superior to others, which should be investigated in the future.
In summary, for cSEMS treatment of ABS, fewer treatment sessions are necessary. Obviously, cSEMSs and MPSs are comparably safe and efficient and achieve a similar outcome. Our study adds evidence to the growing amount of data showing that cSEMS treatment for ABSs is a good alternative to MPSs. However, improved stent models should decrease migration rates of cSEMSs. The optimal duration of cSEMS therapy and cost-efficacy analysis of cSEMSs versus MPSs are subject to future studies.
